OncoViews
  • Therapy Areas
  • Latest
  • CHECK-IN NOW
European Commission Approves New Treatments for Urothelial and Lung Cancer

European Commission Approves New Treatments for Urothelial and Lung Cancer

by EMA Approval | 30 August 2024 | Lung Cancer, Urogenital

The European Commission has approved two new cancer treatments: enfortumab vedotin in combination with pembrolizumab for urothelial cancer and amivantamab-vmjw in combination with chemotherapy for non-small cell lung cancer (NSCLC). These approvals mark significant...
EU to Approve Toripalimab for Advanced Head & Neck, & Zolbetuximab in GEJ cancer

EU to Approve Toripalimab for Advanced Head & Neck, & Zolbetuximab in GEJ cancer

by EMA Approval | 31 July 2024 | Gastrointestinal

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recently recommended the approval of several new treatments for advanced cancers, including toripalimab-tpzi for nasopharyngeal carcinoma (NPC) and esophageal squamous cell...
Swissmedic Approves Alectinib In Early Stage ALK+ NSCLC

Swissmedic Approves Alectinib In Early Stage ALK+ NSCLC

by Swiss Approval | 26 July 2024 | Lung Cancer

Alectinib has been approved by the Swissmedic as a monotherapy for adjuvant treatment in adult patients with ALK-positive stage IB (tumor ≥4cm) to IIIA non-small cell lung cancer after complete tumor resection. The recommended dose is 600 mg twice daily. It is...
HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

HER2-Expressing Gynecological Cancers: Catching Up on Targeted Approaches

by Ilaria Colombo | 19 July 2024 | Women's Cancers

Compared to other tumor types, the development of HER2-targeted therapies for gynecological malignancies is lagging somewhat behind. Nevertheless, promising data have already been generated in the treatment of endometrial, cervical, and ovarian cancer.  © Freepik |...
Our New Partnership with Universimed and Leading Opinions

Our New Partnership with Universimed and Leading Opinions

by PEAK Medicals | 17 July 2024 | OncoNews

We are thrilled to announce our new partnership with Universimed, a renowned medical publisher, and their esteemed journal, Leading Opinions. This collaboration marks a significant step forward in our commitment to advancing oncology education.  © OncoViews As part of...
« Older Entries
Next Entries »

Recent Posts

  • Swissmedic Approvals Expand Options for HR+ Metastatic Breast Cancer: Trastuzumab Deruxtecan and Datopotamab Deruxtecan
  • Antibody-Drug Conjugates in Breast Cancer: Advancing Precision Treatment
  • Diagnosis of Lung Cancer: Biomarker Testing on the Road to the Future
  • Advancing Frontline Treatment: Managing Enfortumab Vedotin and Pembrolizumab Toxicities in Metastatic Urothelial Cancer
  • Endometrial Cancer: A Revolution That Is Only Just Beginning

Recent Comments

  1. Swissmedic Approvals Expand Options for HR+ Metastatic Breast Cancer: Trastuzumab Deruxtecan and Datopotamab Deruxtecan | OncoViews on Breast Cancer Subtype Definitions (1/4)

Share your patient case for discussion

Let our faculty discuss your patient case during the roundtables - rest assured, we'll keep you posted!

submit patient case

Quick Links

Twitter
LinkedIn
Contact
Terms Of Use
Privacy Policy
Legal Notice

Our Partners

Leading Opinions

Choose your area of interest

Join our network and become an OncoViewer!

SIGN UP FOR FREE
Lung Icon

Lung Cancer

NSCLC, Mesothelioma, SCLC
Uterus Icon

Women's Cancers

Breast Cancer, Gynecologic Cancers
GI Icon

Gastrointestinal

Upper & Lower GI, Pancreatic, HCC
Bladder Icon

Urogenital

Renal, Urothelial & Prostate
Hematology Icon

Hematology

Hodgkin- & Non-Hodgkin Lymphomas
Other Solid Tumor Icon

Other Solid Tumors

Melanoma, Head & Neck Cancer, etc

Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}